 Shyam Raghavan
Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 21 | 2024 | 825 | 7.150 |
Why?
| | Melanoma | 7 | 2024 | 730 | 3.240 |
Why?
| | Biomarkers, Tumor | 10 | 2024 | 1181 | 2.020 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 4 | 2020 | 8 | 1.730 |
Why?
| | Nevus, Pigmented | 2 | 2024 | 32 | 1.550 |
Why?
| | Antigens, Neoplasm | 4 | 2024 | 309 | 1.520 |
Why?
| | Diagnosis, Differential | 12 | 2024 | 1434 | 1.120 |
Why?
| | Tendons | 5 | 2016 | 106 | 1.010 |
Why?
| | Genes, T-Cell Receptor gamma | 2 | 2021 | 3 | 0.950 |
Why?
| | Merkel cell polyomavirus | 1 | 2024 | 4 | 0.920 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2024 | 18 | 0.900 |
Why?
| | Carcinoma, Basal Cell | 2 | 2022 | 74 | 0.890 |
Why?
| | Nevus | 1 | 2024 | 24 | 0.870 |
Why?
| | Cloning, Molecular | 2 | 2021 | 524 | 0.870 |
Why?
| | Immunohistochemistry | 8 | 2024 | 1698 | 0.860 |
Why?
| | Melanocytes | 2 | 2022 | 64 | 0.860 |
Why?
| | Xeroderma Pigmentosum | 1 | 2022 | 7 | 0.790 |
Why?
| | Hamartoma | 1 | 2022 | 20 | 0.780 |
Why?
| | Granular Cell Tumor | 1 | 2022 | 7 | 0.770 |
Why?
| | Pityriasis Lichenoides | 1 | 2021 | 1 | 0.760 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2021 | 21 | 0.760 |
Why?
| | Pathologists | 1 | 2022 | 17 | 0.760 |
Why?
| | Mycosis Fungoides | 2 | 2018 | 61 | 0.750 |
Why?
| | Tissue Engineering | 5 | 2016 | 396 | 0.750 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2020 | 201 | 0.750 |
Why?
| | Rhabdoid Tumor | 1 | 2022 | 98 | 0.740 |
Why?
| | Lymphoproliferative Disorders | 1 | 2021 | 54 | 0.740 |
Why?
| | Syphilis | 1 | 2021 | 32 | 0.730 |
Why?
| | Bone Neoplasms | 1 | 2024 | 231 | 0.730 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2020 | 18 | 0.710 |
Why?
| | Lymphoid Enhancer-Binding Factor 1 | 1 | 2020 | 6 | 0.710 |
Why?
| | Carcinoma | 1 | 2022 | 217 | 0.710 |
Why?
| | Sarcoma, Clear Cell | 1 | 2020 | 8 | 0.700 |
Why?
| | Keratin-7 | 1 | 2020 | 2 | 0.700 |
Why?
| | Eyelid Neoplasms | 1 | 2020 | 9 | 0.690 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2020 | 9 | 0.690 |
Why?
| | Immunocompromised Host | 1 | 2021 | 198 | 0.670 |
Why?
| | Skin Diseases | 1 | 2021 | 143 | 0.660 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2019 | 10 | 0.650 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2019 | 20 | 0.650 |
Why?
| | Ki-1 Antigen | 1 | 2018 | 4 | 0.620 |
Why?
| | Receptors, Androgen | 1 | 2020 | 147 | 0.620 |
Why?
| | Cadherins | 1 | 2020 | 188 | 0.610 |
Why?
| | Skin | 5 | 2024 | 725 | 0.610 |
Why?
| | Ki-67 Antigen | 1 | 2018 | 109 | 0.600 |
Why?
| | Humans | 57 | 2024 | 129622 | 0.590 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 43 | 0.570 |
Why?
| | Antigens, CD | 1 | 2020 | 489 | 0.560 |
Why?
| | Exanthema | 3 | 2023 | 74 | 0.560 |
Why?
| | Tissue Scaffolds | 4 | 2016 | 201 | 0.530 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 328 | 0.520 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2024 | 212 | 0.510 |
Why?
| | Kidney Transplantation | 1 | 2021 | 672 | 0.480 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2018 | 511 | 0.460 |
Why?
| | Mastectomy | 1 | 2015 | 131 | 0.450 |
Why?
| | Aged | 14 | 2024 | 22099 | 0.440 |
Why?
| | Skin Abnormalities | 2 | 2023 | 12 | 0.430 |
Why?
| | Cell Proliferation | 2 | 2020 | 2391 | 0.420 |
Why?
| | Mammaplasty | 1 | 2015 | 98 | 0.420 |
Why?
| | Female | 29 | 2024 | 68770 | 0.410 |
Why?
| | Aged, 80 and over | 9 | 2024 | 7084 | 0.400 |
Why?
| | Foot | 2 | 2023 | 93 | 0.390 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2012 | 35 | 0.390 |
Why?
| | Male | 23 | 2024 | 63674 | 0.380 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2012 | 85 | 0.370 |
Why?
| | Appendix | 1 | 2021 | 27 | 0.370 |
Why?
| | Mutation | 5 | 2024 | 3717 | 0.370 |
Why?
| | Adipose Tissue | 2 | 2013 | 592 | 0.370 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2021 | 46 | 0.370 |
Why?
| | Stem Cells | 2 | 2013 | 577 | 0.360 |
Why?
| | Drug Eruptions | 2 | 2020 | 27 | 0.350 |
Why?
| | DNA Mutational Analysis | 2 | 2024 | 387 | 0.350 |
Why?
| | Stomach Neoplasms | 1 | 2021 | 99 | 0.350 |
Why?
| | Postoperative Complications | 1 | 2021 | 2483 | 0.340 |
Why?
| | Duodenum | 3 | 2024 | 75 | 0.330 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2012 | 307 | 0.320 |
Why?
| | Middle Aged | 15 | 2024 | 31150 | 0.320 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2021 | 487 | 0.310 |
Why?
| | Fibroblasts | 1 | 2012 | 948 | 0.270 |
Why?
| | Intestinal Diseases | 2 | 2024 | 36 | 0.260 |
Why?
| | Pancreatic Neoplasms | 2 | 2024 | 882 | 0.260 |
Why?
| | Celiac Disease | 3 | 2024 | 286 | 0.250 |
Why?
| | Prognosis | 3 | 2024 | 3794 | 0.250 |
Why?
| | Soft Tissue Neoplasms | 2 | 2021 | 112 | 0.240 |
Why?
| | Antigens, Viral, Tumor | 1 | 2024 | 7 | 0.230 |
Why?
| | Hematoxylin | 1 | 2024 | 5 | 0.230 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2024 | 9 | 0.230 |
Why?
| | Adult | 13 | 2023 | 35572 | 0.230 |
Why?
| | Extremities | 2 | 2024 | 127 | 0.230 |
Why?
| | Polyomavirus Infections | 1 | 2024 | 28 | 0.220 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2024 | 270 | 0.220 |
Why?
| | Necrobiosis Lipoidica | 1 | 2023 | 2 | 0.220 |
Why?
| | Livedo Reticularis | 1 | 2023 | 4 | 0.220 |
Why?
| | Tattooing | 1 | 2023 | 14 | 0.210 |
Why?
| | Leg | 2 | 2023 | 238 | 0.210 |
Why?
| | Retrospective Studies | 6 | 2024 | 14519 | 0.200 |
Why?
| | Esophagogastric Junction | 1 | 2022 | 50 | 0.200 |
Why?
| | Child, Preschool | 6 | 2024 | 10518 | 0.200 |
Why?
| | Child | 8 | 2024 | 20882 | 0.200 |
Why?
| | Comparative Genomic Hybridization | 1 | 2022 | 32 | 0.200 |
Why?
| | Insulins | 1 | 2023 | 37 | 0.190 |
Why?
| | S100 Proteins | 1 | 2022 | 36 | 0.190 |
Why?
| | Uveitis, Anterior | 1 | 2021 | 13 | 0.190 |
Why?
| | Lymphoma, T-Cell | 1 | 2021 | 23 | 0.190 |
Why?
| | Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 | 2021 | 1 | 0.190 |
Why?
| | Mesenchymoma | 1 | 2021 | 7 | 0.190 |
Why?
| | Pemphigus | 1 | 2021 | 8 | 0.180 |
Why?
| | DNA Helicases | 1 | 2022 | 149 | 0.180 |
Why?
| | Erythema | 1 | 2021 | 28 | 0.180 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2021 | 17 | 0.180 |
Why?
| | Liposarcoma, Myxoid | 1 | 2021 | 9 | 0.180 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 30 | 0.180 |
Why?
| | Nevus, Blue | 1 | 2020 | 2 | 0.180 |
Why?
| | Dysplastic Nevus Syndrome | 1 | 2020 | 2 | 0.180 |
Why?
| | Phospholipids | 1 | 2022 | 215 | 0.180 |
Why?
| | Scrotum | 1 | 2020 | 26 | 0.180 |
Why?
| | Lymphoma, B-Cell | 1 | 2022 | 105 | 0.180 |
Why?
| | Biopsy | 2 | 2024 | 1097 | 0.170 |
Why?
| | Histiocytes | 1 | 2020 | 7 | 0.170 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2020 | 60 | 0.170 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2020 | 42 | 0.170 |
Why?
| | Smooth Muscle Tumor | 1 | 2020 | 6 | 0.170 |
Why?
| | Adolescent | 6 | 2022 | 20391 | 0.170 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1206 | 0.160 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2020 | 210 | 0.160 |
Why?
| | Paired Box Transcription Factors | 1 | 2019 | 40 | 0.160 |
Why?
| | Ehlers-Danlos Syndrome | 1 | 2019 | 16 | 0.160 |
Why?
| | Hodgkin Disease | 1 | 2021 | 134 | 0.160 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2019 | 5 | 0.160 |
Why?
| | Myositis, Inclusion Body | 1 | 2019 | 8 | 0.160 |
Why?
| | Intestinal Perforation | 1 | 2019 | 45 | 0.160 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2020 | 158 | 0.160 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2020 | 72 | 0.160 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 261 | 0.160 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 318 | 0.150 |
Why?
| | Sjogren's Syndrome | 1 | 2019 | 48 | 0.150 |
Why?
| | Surgical Flaps | 1 | 2020 | 135 | 0.150 |
Why?
| | beta Catenin | 1 | 2020 | 223 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 181 | 0.150 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 259 | 0.150 |
Why?
| | Tumor Suppressor Proteins | 1 | 2020 | 317 | 0.150 |
Why?
| | Nuclear Proteins | 1 | 2022 | 663 | 0.140 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2020 | 228 | 0.140 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 426 | 0.140 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2020 | 432 | 0.140 |
Why?
| | Proto-Oncogene Proteins | 1 | 2020 | 638 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 964 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 626 | 0.130 |
Why?
| | Hospitals, County | 1 | 2016 | 10 | 0.130 |
Why?
| | Pericardium | 1 | 2016 | 54 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2020 | 743 | 0.130 |
Why?
| | Wrist Injuries | 1 | 2016 | 28 | 0.130 |
Why?
| | Lacerations | 1 | 2016 | 29 | 0.130 |
Why?
| | Peripheral Nerve Injuries | 1 | 2016 | 36 | 0.130 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 1838 | 0.120 |
Why?
| | Cohort Studies | 3 | 2024 | 5420 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 759 | 0.120 |
Why?
| | RNA | 1 | 2022 | 883 | 0.120 |
Why?
| | Lower Extremity | 3 | 2023 | 404 | 0.120 |
Why?
| | Organ Sparing Treatments | 1 | 2015 | 32 | 0.120 |
Why?
| | Intestinal Mucosa | 3 | 2024 | 590 | 0.120 |
Why?
| | Transcription Factors | 1 | 2022 | 1651 | 0.110 |
Why?
| | Pakistan | 2 | 2024 | 75 | 0.110 |
Why?
| | Zambia | 2 | 2024 | 55 | 0.110 |
Why?
| | Microvessels | 1 | 2015 | 83 | 0.110 |
Why?
| | Breast | 1 | 2015 | 153 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1367 | 0.110 |
Why?
| | Transcriptome | 1 | 2019 | 887 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2020 | 1928 | 0.100 |
Why?
| | Patient Compliance | 1 | 2016 | 565 | 0.100 |
Why?
| | Inflammation | 1 | 2023 | 2736 | 0.100 |
Why?
| | Polymers | 2 | 2023 | 479 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 330 | 0.090 |
Why?
| | Collagen | 1 | 2013 | 434 | 0.090 |
Why?
| | Bioreactors | 1 | 2011 | 43 | 0.090 |
Why?
| | Drug Synergism | 1 | 2012 | 371 | 0.090 |
Why?
| | Rats, Wistar | 1 | 2011 | 441 | 0.090 |
Why?
| | Rabbits | 1 | 2011 | 778 | 0.080 |
Why?
| | Prospective Studies | 3 | 2023 | 7131 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 634 | 0.080 |
Why?
| | Extracellular Matrix | 2 | 2024 | 504 | 0.080 |
Why?
| | Vascular Surgical Procedures | 2 | 2009 | 294 | 0.080 |
Why?
| | Vascular Neoplasms | 1 | 2009 | 17 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2020 | 10226 | 0.080 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2009 | 24 | 0.080 |
Why?
| | Angioplasty | 1 | 2009 | 47 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 2061 | 0.080 |
Why?
| | Colon | 1 | 2021 | 254 | 0.080 |
Why?
| | Esophagus | 1 | 2021 | 248 | 0.080 |
Why?
| | Young Adult | 4 | 2020 | 12426 | 0.080 |
Why?
| | Vaccines, DNA | 1 | 2008 | 28 | 0.070 |
Why?
| | Polyethyleneimine | 1 | 2008 | 18 | 0.070 |
Why?
| | Microspheres | 1 | 2008 | 127 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2013 | 4083 | 0.070 |
Why?
| | Sarcoma | 1 | 2009 | 176 | 0.070 |
Why?
| | Education, Medical, Undergraduate | 1 | 2009 | 176 | 0.070 |
Why?
| | Animals | 6 | 2023 | 35360 | 0.060 |
Why?
| | Computer Simulation | 1 | 2009 | 943 | 0.060 |
Why?
| | Goblet Cells | 1 | 2024 | 18 | 0.060 |
Why?
| | Child Nutrition Disorders | 1 | 2024 | 19 | 0.060 |
Why?
| | Bangladesh | 1 | 2024 | 45 | 0.060 |
Why?
| | Milk Proteins | 1 | 2023 | 33 | 0.050 |
Why?
| | Antigen-Antibody Complex | 1 | 2023 | 84 | 0.050 |
Why?
| | Intestine, Small | 1 | 2024 | 150 | 0.050 |
Why?
| | Acrylamides | 1 | 2023 | 58 | 0.050 |
Why?
| | Clinical Competence | 1 | 2009 | 1016 | 0.050 |
Why?
| | Risk Assessment | 1 | 2021 | 3240 | 0.050 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2022 | 80 | 0.050 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2021 | 32 | 0.050 |
Why?
| | In Situ Hybridization | 1 | 2022 | 295 | 0.050 |
Why?
| | Hyperplasia | 1 | 2022 | 171 | 0.050 |
Why?
| | Hepatocytes | 1 | 2022 | 216 | 0.050 |
Why?
| | Genes, T-Cell Receptor | 1 | 2020 | 9 | 0.040 |
Why?
| | CD4-CD8 Ratio | 1 | 2020 | 22 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2022 | 98 | 0.040 |
Why?
| | Lip | 1 | 2020 | 22 | 0.040 |
Why?
| | Infant | 2 | 2024 | 9025 | 0.040 |
Why?
| | Cattle | 1 | 2023 | 976 | 0.040 |
Why?
| | Genetic Therapy | 1 | 2022 | 292 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2020 | 69 | 0.040 |
Why?
| | Allergens | 1 | 2023 | 385 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2021 | 376 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 315 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2021 | 151 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2021 | 311 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 320 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 520 | 0.040 |
Why?
| | Ileostomy | 1 | 2019 | 20 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2023 | 847 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2022 | 569 | 0.040 |
Why?
| | Colectomy | 1 | 2019 | 94 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2022 | 1033 | 0.040 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 247 | 0.040 |
Why?
| | Mice | 3 | 2023 | 16937 | 0.040 |
Why?
| | Machine Learning | 1 | 2023 | 443 | 0.040 |
Why?
| | Synoviocytes | 1 | 2016 | 10 | 0.030 |
Why?
| | San Francisco | 1 | 2016 | 51 | 0.030 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2016 | 197 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1007 | 0.030 |
Why?
| | Hydrogels | 1 | 2023 | 638 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 1952 | 0.030 |
Why?
| | Psychology | 1 | 2016 | 82 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 331 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 958 | 0.030 |
Why?
| | Aftercare | 1 | 2016 | 205 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2564 | 0.030 |
Why?
| | Rats | 1 | 2023 | 5499 | 0.030 |
Why?
| | Swine | 1 | 2016 | 760 | 0.030 |
Why?
| | Liver | 1 | 2022 | 1839 | 0.030 |
Why?
| | Cell Survival | 1 | 2016 | 1086 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2013 | 226 | 0.030 |
Why?
| | Disease Progression | 1 | 2020 | 2635 | 0.020 |
Why?
| | Recovery of Function | 1 | 2016 | 642 | 0.020 |
Why?
| | Social Support | 1 | 2016 | 588 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2022 | 5440 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2016 | 1214 | 0.020 |
Why?
| | Mental Health Services | 1 | 2016 | 404 | 0.020 |
Why?
| | Tensile Strength | 1 | 2011 | 93 | 0.020 |
Why?
| | Elastic Modulus | 1 | 2011 | 123 | 0.020 |
Why?
| | Problem-Based Learning | 1 | 2009 | 77 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2009 | 173 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2011 | 764 | 0.020 |
Why?
| | Career Choice | 1 | 2009 | 207 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3408 | 0.020 |
Why?
| | United States | 1 | 2024 | 13900 | 0.020 |
Why?
| | Educational Measurement | 1 | 2009 | 262 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2008 | 310 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 4896 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2009 | 481 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 1902 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 3973 | 0.010 |
Why?
| | Students, Medical | 1 | 2009 | 315 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2008 | 336 | 0.010 |
Why?
| | Kinetics | 1 | 2008 | 1642 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2008 | 1156 | 0.010 |
Why?
| | Curriculum | 1 | 2009 | 916 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2781 | 0.010 |
Why?
|
|
Raghavan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|